In Vitro Study at MD Anderson Cancer Center Labs Shows Mino-Lok Components to be Effective in Completely Eradicating All 10 Strains of Candida Auris Tested
Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a report today on the in vitro efficacy of Mino-Lok against various strains of Candida auris.
Candida auris ("C. auris") is a fungus that causes serious infections. C. auris can cause bloodstream infections and even death, particularly in hospital and nursing home patients with serious medical problems. More than 1 in 3 patients with invasive C. auris infection die. It's often resistant to most antifungal agents commonly used to treat Candida infections. Although C. auris was just discovered in 2009, it has spread quickly and caused infections in more than a dozen countries. Patients who have been hospitalized in a healthcare facility a long time, have a central venous catheter, or other lines or tubes entering their body, or have previously received antibiotics or antifungal medications, appear to be at highest risk of infection with this yeast.
Mr. Myron Holubiak, CEO of Citius, said, "We are very enthused Mino-Lok has shown strong activity against a significant number of C. aurisstrains and that complete eradication occurred within an hour of exposure. Fortunately, our patients have not encountered any C. aurisCLABSIs to date in our clinical trials. While these data for Mino-Lok are highly encouraging as they relate to Candida, in vitro data do not necessarily correlate with clinical results; and, we recognize more work needs to be done. The company is currently studying Mino-Lok in a phase 3 trial in over 40 participating institutions, all located in the U.S."
Blood stream infections due to Candida auris are an emerging public health concern due to high prevalence of antifungal resistance and significant rates of patient mortality. C. auris is typically highly resistant; and, several strains have been identified with elevated MICs to all major classes of antifungals. Previously Citius reported that Mino-Lok was highly effective in clinical trials that evaluated salvage of catheters in patients with highly virulent bacterial infections. In this laboratory study, Mino-Lok was evaluated in its ability to eradicate C. aurisin mature biofilms in vitrowithin an hour of exposure*.
* Data on file.
Mino-Lok®
Mino-Lok is an antibiotic lock solution used to treat patients with CLABSIs/CRBSIs. CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients for whom venous access presents a challenge. There are currently no approved therapies to salvage infected central venous catheters (CVCs).
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
No comments:
Post a Comment